Celgene Corp. (CELG) announced Thursday morning that its subsidiary, Celgene International Sàrl, has decided to withdraw the new indication submission to the Committee for Medicinal Products for Human Use for REVLIMID.
Celgene also reaffirmed its guidance for the full years 2012 and 2015.
Celgene gapped open sharply lower Thursday and is now down 8.46 at $58.70 on above average volume. The stock has dropped to over a 9-month low.
For comments and feedback: editorial@rttnews.com